Affinitak (ISIS 3521 or LY900003) : ISIS Pharmaceuticals : Antisense

Affinitak Phase III Trial Results in NCLC (ISIS Pharmaceuticals)
Press release announcing results of the Phase III trial comparing Affinitak plus carboplatin and paclitaxel to chemotherapy alone. There was no difference in overall survival between the two groups. Discusses additional findings. [3/03]

Phase II Trial of ISIS 3521, an Antisense Inhibitor, with Docetaxel in NSCLC (ASCO)
Phase I/II Trial of ISIS 3521, an Antisense Inhibitor, with Cisplatin and Gemcitabine in Advanced NSCLC (ASCO)
Affinitac, a targeted antisense therapy, used in combination with chemotherapy demonstrated high rates of tumor response and stable disease in the treatment of NSCLC, according to results from Phase II trials presented at the 2002 ASCO annual meeting. [5/02]